Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| MDA-MB-361 | Alvocidib | 1.0 | -0.3951 | 0.08760 |
| MCF7 | THZ1 | 1.0 | -0.3941 | 0.22637 |
| HCC1806 | MK 1775 | 10.0 | -0.3938 | 0.28947 |
| HCC1937 | THZ1 | 1.0 | -0.3919 | 0.12737 |
| SUM149PT | THZ1 | 1.0 | -0.3915 | 0.36547 |
| SUM149PT | MK 1775 | 10.0 | -0.3915 | 0.34098 |
| HCC1428 | THZ531 | 0.1 | -0.3914 | 0.01642 |
| HCC1395 | THZ1 | 0.1 | -0.3902 | 0.16305 |
| HCC1937 | THZ1 | 1.0 | -0.3899 | 0.10901 |
| HCC1500 | MK 1775 | 0.0316227766017 | -0.3894 | -0.20309 |
| MDA-MB-231 | Alvocidib | 1.0 | -0.3881 | 0.39015 |
| SUM149PT | MK 1775 | 10.0 | -0.3868 | 0.39868 |
| AU565 | THZ1 | 1.0 | -0.3863 | 0.40814 |
| AU565 | LY3023414 | 10.0 | -0.3863 | 0.39707 |
| HCC1428 | Ribociclib | 10.0 | -0.3849 | 0.01484 |
| MDA-MB-157 | RO-3306 | 10.0 | -0.3845 | 0.21012 |
| HCC70 | MK 1775 | 1.0 | -0.3839 | 0.14719 |
| CAMA-1 | LY3023414 | 10.0 | -0.3833 | 0.10519 |
| HCC1500 | GSK2334470 | 0.316227766017 | -0.3823 | -0.17859 |
| HCC1419 | THZ1 | 1.0 | -0.3820 | 0.08107 |
| MDA-MB-134-VI | THZ1 | 0.316227766017 | -0.3808 | 0.07084 |
| BT-549 | Alvocidib | 1.0 | -0.3797 | 0.22526 |
| MDA-MB-157 | LY3023414 | 10.0 | -0.3793 | 0.18552 |
| CAMA-1 | THZ531 | 1.0 | -0.3792 | 0.16414 |
| MDA-MB-134-VI | THZ1 | 0.316227766017 | -0.3784 | 0.05725 |